Patents by Inventor Mark Firman Bear

Mark Firman Bear has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9834819
    Abstract: The invention generally relates to methods for diagnosing autism spectrum disorders. In certain embodiments, the invention provides a method for diagnosing presence or increased risk of developing an autism spectrum disorder in a subject.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: December 5, 2017
    Assignee: Laboratory Corporation of America Holdings
    Inventors: David Michael Margulies, Mark Firman Bear
  • Publication number: 20170157218
    Abstract: Disclosed herein are novel methodologies of treating fragile X syndrome and related disorders by inhibiting mG1u5-relevant signaling pathways via the reduction of ?-arrestin2 protein levels or the diminution of mG1u5 and ?-arrestin2 protein interactions.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 8, 2017
    Applicants: Massachusetts Institute of Technology, Duke University
    Inventors: BENJAMIN DAVID AUERBACH, Mark Firman Bear, Laura Jane Stoppel, Robert J. Lefkowitz
  • Publication number: 20170065598
    Abstract: Amblyopia is a prevalent form of visual impairment that generally arises during infancy and early childhood when inputs to the visual cortex form the two eyes are poorly balanced. Disclosed herein are methods involving retinal inactivation of at least one retina to treat visual impairment in the form of amblyopia or other conditions.
    Type: Application
    Filed: August 9, 2016
    Publication date: March 9, 2017
    Applicants: Massachusetts Institute of Technology, Dalhousie University
    Inventors: Mark Firman Bear, Kevin R. Duffy, Donald E. Mitchell, Ming-Fai Fong, Arnold Heynen, Jeffrey P. Gavornik
  • Publication number: 20160375006
    Abstract: The present disclosure provides methods of using GSK3?-selective inhibitors for treating Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder. The GSK3?-selective inhibitors include compounds of Formula I-A. The present disclosure also provides methods of using GSK3?-selective inhibitors for treating a mood disorder, post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorder. The GSK3?-selective inhibitors include compounds of Formula I-B.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 29, 2016
    Inventors: Edward Scolnick, Jeffrey R. Cottrell, Florence Fevrier Wagner, Edward Holson, Michael C. Lewis, Mark Firman Bear, Laura Stoppel, Arnold Heynen
  • Publication number: 20140186839
    Abstract: The invention generally relates to compositions and methods for diagnosing autism spectrum disorders. In certain embodiments, the invention provides a method for diagnosing presence or increased risk of developing an autism spectrum disorder in a subject.
    Type: Application
    Filed: March 17, 2014
    Publication date: July 3, 2014
    Inventors: David Michael Margulies, Mark Firman Bear
  • Publication number: 20110166029
    Abstract: The invention generally relates to compositions and methods for diagnosing autism spectrum disorders. In certain embodiments, the invention provides a method for diagnosing presence or increased risk of developing an autism spectrum disorder in a subject.
    Type: Application
    Filed: September 8, 2010
    Publication date: July 7, 2011
    Inventors: David Michael Margulies, Mark Firman Bear